Benzbromarone (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Benzbromarone" in French language version.

refsWebsite

Global rank French rank

4^th place

12^th place

2^nd place

3^rd place

234^th place

147^th place

low place

1,903^rd place

2,733^rd place

485^th place

416^th place

doi.org

(en) Ichida K, Matsuo H, Takada T et al., « Decreased extra-renal urate excretion is a common cause of hyperuricemia », Nat Commun, vol. 3,‎ 2012, p. 764. (PMID 22473008, PMCID PMC3337984, DOI 10.1038/ncomms1756, lire en ligne)
(en) Okuda C, Koyama H, Tsutsumi Z, Yamamoto A, Kurajoh M, Moriwaki Y, Yamamoto T, « Serum CRP in patients with gout and effects of benzbromarone », Int J Clin Pharmacol Ther, vol. 49, n^o 3,‎ 2011, p. 191–7. (PMID 21329621, DOI 10.5414/cp201425, lire en ligne)
(en) Kadowaki D, Sakaguchi S, Miyamoto Y et al., « Direct radical scavenging activity of benzbromarone provides beneficial antioxidant properties for hyperuricemia treatment », Biol Pharm Bull, vol. 38, n^o 3,‎ 2015, p. 487–92. (PMID 25757933, DOI 10.1248/bpb.b14-00514, lire en ligne)
(en) Kang EH, Park EH, Shin A, Song JS, Kim SC, « Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout », Eur Heart J, vol. 42, n^o 44,‎ 2021, p. 4578–88. (PMID 34508567, DOI 10.1093/eurheartj/ehab619, lire en ligne)

(en) Okuda C, Koyama H, Tsutsumi Z, Yamamoto A, Kurajoh M, Moriwaki Y, Yamamoto T, « Serum CRP in patients with gout and effects of benzbromarone », Int J Clin Pharmacol Ther, vol. 49, n^o 3,‎ 2011, p. 191–7. (PMID 21329621, DOI 10.5414/cp201425, lire en ligne)

(en) Kadowaki D, Sakaguchi S, Miyamoto Y et al., « Direct radical scavenging activity of benzbromarone provides beneficial antioxidant properties for hyperuricemia treatment », Biol Pharm Bull, vol. 38, n^o 3,‎ 2015, p. 487–92. (PMID 25757933, DOI 10.1248/bpb.b14-00514, lire en ligne)

(en) Ichida K, Matsuo H, Takada T et al., « Decreased extra-renal urate excretion is a common cause of hyperuricemia », Nat Commun, vol. 3,‎ 2012, p. 764. (PMID 22473008, PMCID PMC3337984, DOI 10.1038/ncomms1756, lire en ligne)

(en) Ichida K, Matsuo H, Takada T et al., « Decreased extra-renal urate excretion is a common cause of hyperuricemia », Nat Commun, vol. 3,‎ 2012, p. 764. (PMID 22473008, PMCID PMC3337984, DOI 10.1038/ncomms1756, lire en ligne)
(en) Okuda C, Koyama H, Tsutsumi Z, Yamamoto A, Kurajoh M, Moriwaki Y, Yamamoto T, « Serum CRP in patients with gout and effects of benzbromarone », Int J Clin Pharmacol Ther, vol. 49, n^o 3,‎ 2011, p. 191–7. (PMID 21329621, DOI 10.5414/cp201425, lire en ligne)
(en) Kadowaki D, Sakaguchi S, Miyamoto Y et al., « Direct radical scavenging activity of benzbromarone provides beneficial antioxidant properties for hyperuricemia treatment », Biol Pharm Bull, vol. 38, n^o 3,‎ 2015, p. 487–92. (PMID 25757933, DOI 10.1248/bpb.b14-00514, lire en ligne)
(en) Kang EH, Park EH, Shin A, Song JS, Kim SC, « Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout », Eur Heart J, vol. 42, n^o 44,‎ 2021, p. 4578–88. (PMID 34508567, DOI 10.1093/eurheartj/ehab619, lire en ligne)

(en) Kang EH, Park EH, Shin A, Song JS, Kim SC, « Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout », Eur Heart J, vol. 42, n^o 44,‎ 2021, p. 4578–88. (PMID 34508567, DOI 10.1093/eurheartj/ehab619, lire en ligne)